What the FDA labels say about taking them together
Gemfibrozil and ozanimod
Ozanimod's FDA label of April 16, 2026 names gemfibrozil in its drug interactions section; the gemfibrozil labels PlainMeds reads (2) do not name ozanimod. The ozanimod label: “Co-administration of ZEPOSIA with strong CYP2C8 inhibitors increases the exposure of the active metabolites of ozanimod, which may increase the risk of ZEPOSIA adverse reactions.”
Check it at the source: the gemfibrozil FDA label on DailyMed (effective April 10, 2026, Northstar RxLLC); the ozanimod FDA label on DailyMed (effective April 16, 2026, Celgene Corporation).
What does the gemfibrozil label say about ozanimod?
Gemfibrozil's label (effective April 10, 2026) and its 1 other brand-application label do not name ozanimod in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Gemfibrozil), Northstar RxLLC, effective April 10, 2026 (SPL set 75cac02c-56e3-4dfe-b1e2-4ce166b28833), via openFDA; the full label on DailyMed
What does the ozanimod label say about gemfibrozil?
Ozanimod label, drug interactionsStrong CYP2C8 Inhibitors Clinical Impact: Co-administration of ZEPOSIA with strong CYP2C8 inhibitors increases the exposure of the active metabolites of ozanimod [see ], which may increase the risk of ZEPOSIA adverse reactions. Prevention or Management: Co-administration of ZEPOSIA with strong CYP2C8 inhibitors (e.g., gemfibrozil) is not recommended.
Source: FDA drug label (ZEPOSIA 7-Day Starter Pack), NDA209899 (Bristol), as published by Celgene Corporation, effective April 16, 2026 (SPL set 93ce2fab-edfb-4804-8074-963071de51e4), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Gemfibrozil | Ozanimod | |
|---|---|---|
| Labeled for | High cholesterol, Heart attack and coronary artery disease | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.104 per tablet 600 mg tablet | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once